News | July 03, 2024
Avallano appoints Michael A. Ibara as Chief Strategy Officer
Ibara will drive AI-powered clinical research innovation
Ibara will drive AI-powered clinical research innovation
Imfinzi also recommended for patients with mismatch repair deficient disease
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Renews GMP certifications for India and Malaysia sites
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Subscribe To Our Newsletter & Stay Updated
